Tirzepatide GI Side Effects
Tirzepatide Constipation: Why It Happens and How to Manage It
Tirzepatide constipation comes from the same slowed gut motility that drives the appetite effect: stool moves through the colon more slowly, the colon pulls out more water, and what is left is harder and harder to pass. How often it happens depends heavily on which trial population you look at. The FDA label for Mounjaro reports constipation in 6% to 7% of people with type 2 diabetes across its 5mg to 15mg doses, while the Zepbound label reports 11% to 17% in its obesity trials. Those are different studies in different populations, and this guide keeps them separate instead of blending them into one number.
Key Takeaways
- Tirzepatide slows gastric emptying and intestinal transit. Slower transit gives the colon more time to reabsorb water, which produces harder, drier stool.
- Reported rates differ sharply by trial program. Mounjaro's type 2 diabetes trials reported 6% to 7% constipation across 5mg to 15mg against 1% on placebo. Zepbound's obesity trials reported 11% to 17% against 5% on placebo.
- Those two figures come from separate trial programs in separate populations. They are not a head-to-head comparison of the two brands.
- Eating less works against you here: less fiber and less fluid reach a gut that is already moving slowly. Neither label reports how long constipation lasts, so treat that as a reason it can be stubborn, not as a documented timeline.
- Both labels list ileus, intestinal obstruction, and severe constipation including fecal impaction among postmarketing gastrointestinal reports. Constipation on tirzepatide is not always a minor inconvenience, and some symptoms need urgent care rather than home management.
6-7%
Mounjaro, type 2 diabetes trials
11-17%
Zepbound, obesity trials
~5 days
Half-life, steady weekly levels
4 weeks
Standard interval between dose steps
Why Tirzepatide Causes Constipation
Tirzepatide is a dual agonist at the GLP-1 and GIP receptors. Activating GLP-1 receptors slows how fast the stomach empties into the small intestine, and it slows transit further downstream as well. That delay is not a side effect bolted onto the drug; it is part of how the drug produces fullness and reduced appetite.
Constipation is what happens when that same slowdown reaches the colon. The colon's main job is reabsorbing water from what passes through it. Give it more time with the same material and it takes out more water. Stool ends up drier, firmer, and harder to move. This is a different downstream consequence of the same mechanism that produces nausea, which is why the two symptoms often show up in the same person but do not behave the same way.
Why it can outlast nausea
Neither label reports how long any gastrointestinal symptom lasts, so what follows is reasoning from the mechanism rather than a documented finding. Constipation has a second driver that nausea does not. Eating less means less fiber and less bulk entering the gut, and people eating noticeably less tend to drink less as well. The mechanical slowdown therefore gets a smaller, drier input stream to work with. That is a plausible reason some people find constipation more stubborn than the queasiness, but it has not been measured in either trial program.
The gastroparesis boundary
Both the Mounjaro and Zepbound prescribing information state that tirzepatide is not recommended in patients with severe gastroparesis. That instruction sits at the far end of the same mechanism: if gastric motility is already badly impaired, adding a drug that slows it further is a poor trade. If you have a diagnosed motility disorder or a history of bowel disease, that belongs in the conversation with your prescriber before you start, not after symptoms appear. The complete tirzepatide side effects guide covers the wider adverse-reaction picture.
Map Your Dose Schedule Week by Week
Lay out your titration steps and weekly plasma levels so you have a concrete timeline to note symptoms against. The GLP3Planner calculator is free.
Open the Tirzepatide Calculator →How Common Is Tirzepatide Constipation? Mounjaro and Zepbound, Split by Population
Mounjaro and Zepbound are the same molecule, but they were studied in different trial programs, in different patient populations, against different comparator arms. The prescribing information for each brand reports its own adverse-reaction table, and the constipation figures are not the same. A lot of published guidance quotes one figure for both brands, which is where the confusion comes from.
Mounjaro: type 2 diabetes population
These rates come from the pooled placebo-controlled trials in the Mounjaro prescribing information, Section 6.1. The population is adults with type 2 diabetes.
Zepbound: obesity and weight-management population
These rates come from the pooled placebo-controlled weight-reduction trials in the Zepbound prescribing information, Section 6.1. The population is adults treated for obesity or overweight.
Read these two tables separately. They come from separate trial programs that enrolled different patients, on different background medications, against placebo arms that themselves behaved differently (1% versus 5%). Two harder reasons sit underneath that. The two labels use different reporting thresholds, Mounjaro's table listing reactions occurring in at least 5% of treated patients and Zepbound's at least 2%, and Zepbound's constipation row is a composite that also counts hard stool, while Mounjaro's is not. Different case definitions alone would make the figures non-comparable even if the populations were identical. Putting them near each other is a layout choice, not a comparison. Nothing in either label supports the statement that one brand causes more constipation than the other.
The Zepbound numbers run backwards, and the label does not say why
In the Zepbound table the highest constipation rate sits at the lowest dose, 17% at 5mg, falling to 11% at 15mg. That is not a transcription error. The label reports the numbers and offers no explanation for the direction they run. Nothing in the prescribing information accounts for it, so treat any confident explanation you read elsewhere as speculation.
The practical read is that constipation on tirzepatide does not track cleanly with dose. If you are constipated at 5mg, that is consistent with what the trials recorded, and it does not automatically mean your dose is wrong. Dose questions belong with your prescriber, and the tirzepatide dosing guide covers the standard 2.5mg to 15mg escalation for context.
Managing Tirzepatide Constipation: What to Raise With Your Prescriber
Everything below is general education about approaches clinicians commonly discuss, not a protocol to run on your own. Nothing here includes a product or a dose, deliberately: the right choice depends on your medical history, your other medications, and what is actually causing the problem.
Fluid intake
Since the underlying problem is water being pulled out of stool, fluid intake matters more here than it does for ordinary constipation. The practical difficulty is that people eating noticeably less on tirzepatide often drink less too, so total intake drifts down without anyone deciding to cut it. Drinking on a schedule through the day, rather than only when it occurs to you, is the usual way clinicians suggest working around that.
Fiber, increased gradually
Fiber-rich foods such as vegetables, fruit, oats, and legumes add bulk that a slow gut can work with. The standard caution applies with extra force here: adding a large amount of fiber quickly to a gut that is already moving slowly, without matching fluid, can make bloating and discomfort worse rather than better. Gradual is the operative word. Fiber supplements are a category your care team may raise, and whether one suits you depends on your history.
Movement
Physical activity supports gut motility. Walking is the version most people can sustain daily without building their schedule around it, and it costs nothing, which is why it turns up in almost any clinical conversation about constipation whatever the cause.
Timing around dose steps
The standard titration moves 2.5mg to 5mg to 7.5mg to 10mg to 12.5mg to 15mg at roughly four-week intervals. Many people report GI symptoms feeling worse for a stretch after a dose increase, but neither label reports a symptom timecourse, and the constipation figures in the tables above do not climb with dose. Treat that as something to watch for in yourself rather than something to expect. What is established is the pharmacokinetics: tirzepatide has a half-life of about 5 days, so weekly dosing holds plasma concentrations fairly level rather than letting them fall away between injections. Steady exposure across the week is a reason to keep fluid, fiber, and movement steady across the week too.
Over-the-counter options
When the non-drug approaches are not enough, prescribers commonly discuss over-the-counter categories including osmotic laxatives, stool softeners, and fiber supplements. Which category fits, whether it fits at all, and how it interacts with your other medications is a clinical judgement rather than a general recommendation, so raise it with your care team rather than working from a forum thread. Anyone with a history of bowel obstruction, inflammatory bowel disease, or a motility disorder has a stronger reason than most to get that advice first.
Watch: Constipation on GLP-1 Agonists
An obesity-medicine physician walks through why constipation shows up across the GLP-1 class, what changes tend to help, and the point at which it stops being a manageable nuisance. The class-level explanation applies directly to tirzepatide.
When It Is More Than Simple Constipation
This section is the reason constipation on tirzepatide should not be filed away as a minor annoyance. The postmarketing experience sections of both prescribing information documents list gastrointestinal reports that go well beyond discomfort.
From the postmarketing gastrointestinal reports on the tirzepatide label
The label lists, among gastrointestinal postmarketing reports, "ileus, intestinal obstruction, severe constipation including fecal impaction."
Postmarketing reports come from voluntary reporting in a population of uncertain size, so they cannot be converted into a rate. They establish that these events have been reported, not how often they occur.
Symptoms that warrant urgent medical attention
Seek urgent care rather than trying to manage these at home:
- Inability to pass stool or gas. The gas part matters: it is the sign that distinguishes a blockage from ordinary slow transit.
- Severe or worsening abdominal pain
- A visibly swollen or distended abdomen
- Vomiting, particularly alongside abdominal pain or distension
- No bowel movement for an extended stretch, especially with any of the above
A case report presented at ENDO 2023 describes partial small bowel obstruction in a patient taking tirzepatide (Mathew et al.). A single case report, and a conference abstract at that, says nothing about how likely this is, and it should not be read as a probability. It does show that the label's postmarketing language describes something that has occurred in practice, which is a reason to take the warning signs above seriously rather than wait them out.
When to Talk to Your Clinician
Below the emergency threshold there is a wide band where constipation is not dangerous but is also not something to simply tolerate indefinitely. Reasons to raise it at a routine appointment or by message:
- Constipation that has not improved after a couple of weeks at a stable dose despite fluid, fiber, and movement changes
- Symptoms that are interfering with work, sleep, or daily routine
- Straining that has produced pain, bleeding, or hemorrhoids
- Any history of bowel disease, prior obstruction, or a diagnosed motility disorder
- Alternating constipation and diarrhea, or any pattern that has changed noticeably
Bringing a rough record helps: how many days between bowel movements, what you have already tried, and where you are in the titration schedule. That turns a vague complaint into something your clinician can act on in a short appointment.
Quick-Reference Checklist
- Check for red flags first. No gas passing, severe abdominal pain, distension, or vomiting means urgent care, not home management.
- Drink on a schedule so total fluid intake does not drift down alongside how much you are eating.
- Increase fiber gradually alongside the fluid, not ahead of it.
- Add daily movement, walking included, and keep it consistent.
- Keep a written record of how many days pass between bowel movements. The trial figures do not climb with dose, so do not assume a recent dose step is the cause; a record is what makes a short appointment useful.
- Take it to your prescriber if two weeks of the above have not shifted it. Any over-the-counter option is their call, not a self-directed experiment.
Frequently Asked Questions
How do you stop constipation on tirzepatide?
Consistent fluid intake, a gradual increase in fiber, and daily movement are the non-drug approaches clinicians discuss first. If those do not shift it, a prescriber may raise an over-the-counter category such as a fiber supplement, osmotic laxative, or stool softener. Which one suits you depends on your history, so that is a conversation with your care team.
Can tirzepatide cause fecal impaction?
Severe constipation including fecal impaction appears among the postmarketing gastrointestinal reports on the tirzepatide prescribing information, alongside ileus and intestinal obstruction. Those reports are voluntary, so no rate can be calculated from them. Inability to pass stool or gas, worsening abdominal pain, and abdominal distension are reasons to seek urgent care.
Is it normal to go a week without a bowel movement on tirzepatide?
A full week is outside the range of mild constipation and is a reason to contact your clinician rather than wait longer, particularly with bloating, abdominal pain, or reduced ability to pass gas. Intestinal obstruction and severe constipation appear in tirzepatide's postmarketing reports, so a prolonged stretch should not be self-managed.
How long does tirzepatide constipation last?
Neither the Mounjaro nor the Zepbound label reports how long constipation lasts, so there is no established timeline. Some people report it easing over weeks. Others find it persists, plausibly because eating less keeps fiber and fluid intake low the whole time. Ongoing management rather than a one-time fix is worth raising with a prescriber.
Does constipation mean my tirzepatide dose is too high?
Not necessarily. In Zepbound's obesity trials the reported constipation rate was highest at 5mg and lowest at 15mg, so it does not follow a clean dose-response pattern. The label reports those figures without explaining the direction. Any dose change should be decided with your prescriber rather than in response to this symptom alone.
Is constipation worse with Zepbound or Mounjaro?
The published rates differ, but the trials do not support ranking the brands. Zepbound's obesity trials reported 11% to 17% depending on dose against 5% on placebo. Mounjaro's type 2 diabetes trials reported 6% to 7% against 1% on placebo. Different populations, different comparator arms, so this is not a head-to-head comparison.
What foods and habits help with constipation on tirzepatide?
Fiber-rich foods such as vegetables, fruit, oats, and legumes, increased gradually, plus fluid spread through the day and regular walking. Because you are eating less overall, fluid and fiber intake tends to fall without any deliberate choice, so keeping both up on a schedule is the shift that matters most.
How does tirzepatide constipation compare with semaglutide?
Both slow gastrointestinal motility through GLP-1 receptor activity, and both list constipation as a common adverse reaction. Reported figures come from separate trial programs with separate populations and comparator arms, so they cannot be lined up as a ranking. See the semaglutide side effects guide for that drug's own label data.
When should I call a doctor about constipation on tirzepatide?
Urgently for severe or worsening abdominal pain, inability to pass gas or stool, abdominal swelling, or vomiting. Routinely if constipation has not improved over roughly two weeks of fluid, fiber, and movement changes, or if you have a history of bowel disease. The urgent symptoms can indicate obstruction, which appears in tirzepatide's postmarketing reports.
Plan Your Tirzepatide Schedule
Lay out your titration steps and weekly plasma levels so you can see how symptoms line up with dose changes. The GLP3Planner calculator is free.
Open the Tirzepatide Calculator →References
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Full Prescribing Information, Sections 6.1 and 6.2. Revised 4/2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Full Prescribing Information, Sections 6.1 and 6.2. Revised 4/2026. dailymed.nlm.nih.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. pubmed.ncbi.nlm.nih.gov
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. pubmed.ncbi.nlm.nih.gov
- Schneck KB, Ito M, Tham LS, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024;13(3):494-503. pubmed.ncbi.nlm.nih.gov
- Mathew A, Hannoodee H, et al. FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report. J Endocr Soc. 2023;7(Suppl 1):bvad114.862. pmc.ncbi.nlm.nih.gov
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. It names no specific over-the-counter product and gives no dosing instruction for any laxative, stool softener, or fiber supplement, because those decisions depend on individual medical history. Incidence figures are drawn from the current Mounjaro and Zepbound prescribing information and are reported separately by brand and trial population. Consult a licensed healthcare provider before starting, adjusting, or stopping any medication, and seek urgent care for severe abdominal pain, vomiting, abdominal distension, or an inability to pass stool or gas.
Related Articles
Tirzepatide Side Effects
The complete tirzepatide side effects guide across GI and systemic reactions.
Tirzepatide Dosing Guide
The full 2.5mg to 15mg titration timeline and what each step involves.
Zepbound Side Effects
Brand-specific side effect detail for the weight-management indication.
Mounjaro for Type 2 Diabetes
Context on the diabetes population behind the Mounjaro trial data.